Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today ...

CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics and headquartered in Switzerland, ...

US President Donald Trump kicked off his second term with a series of directives aimed at the US National Institutes of ...

A strange thing happened weeks before the Food and Drug Administration approved the first treatment made with CRISPR gene editing ... the biotech that co-developed the therapy, laid off about ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company with a market capitalization of $240 million, recently reported that its Chief Scientific Officer, Carter Todd Alfred, sold 5,413 ...

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch ...

Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...